1. Home
  2. VOR vs DBVT Comparison

VOR vs DBVT Comparison

Compare VOR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VOR
  • DBVT
  • Stock Information
  • Founded
  • VOR 2015
  • DBVT 2002
  • Country
  • VOR United States
  • DBVT France
  • Employees
  • VOR N/A
  • DBVT N/A
  • Industry
  • VOR Biotechnology: Pharmaceutical Preparations
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VOR Health Care
  • DBVT Health Care
  • Exchange
  • VOR Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • VOR 59.3M
  • DBVT 67.8M
  • IPO Year
  • VOR 2021
  • DBVT N/A
  • Fundamental
  • Price
  • VOR $0.79
  • DBVT $0.48
  • Analyst Decision
  • VOR Strong Buy
  • DBVT Strong Buy
  • Analyst Count
  • VOR 7
  • DBVT 2
  • Target Price
  • VOR $11.36
  • DBVT $6.00
  • AVG Volume (30 Days)
  • VOR 612.6K
  • DBVT 187.5K
  • Earning Date
  • VOR 11-07-2024
  • DBVT 11-06-2024
  • Dividend Yield
  • VOR N/A
  • DBVT N/A
  • EPS Growth
  • VOR N/A
  • DBVT N/A
  • EPS
  • VOR N/A
  • DBVT N/A
  • Revenue
  • VOR N/A
  • DBVT $12,515,000.00
  • Revenue This Year
  • VOR N/A
  • DBVT N/A
  • Revenue Next Year
  • VOR N/A
  • DBVT $2,860.00
  • P/E Ratio
  • VOR N/A
  • DBVT N/A
  • Revenue Growth
  • VOR N/A
  • DBVT 125.54
  • 52 Week Low
  • VOR $0.63
  • DBVT $0.44
  • 52 Week High
  • VOR $3.14
  • DBVT $2.14
  • Technical
  • Relative Strength Index (RSI)
  • VOR 46.07
  • DBVT 28.23
  • Support Level
  • VOR $0.72
  • DBVT $0.44
  • Resistance Level
  • VOR $0.82
  • DBVT $0.81
  • Average True Range (ATR)
  • VOR 0.08
  • DBVT 0.06
  • MACD
  • VOR -0.01
  • DBVT -0.03
  • Stochastic Oscillator
  • VOR 17.71
  • DBVT 10.60

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Share on Social Networks: